Physician profile
Khalid Bashir
NPI 1013021815
$2,492.23
in general payments reported to CMS, 2019-2025
21 companies · $607 in 2025
The $607 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $141 · 2021: $122 · 2022: $451 · 2023: $365 · 2024: $630 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,562 · Education: $40.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,562.07 |
| Education | $40.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $658.12 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $332.56 | 2019-2024 | Jynarque |
| Astrazeneca Pharmaceuticals Lp | $213.93 | 2019-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.98 | 2024-2025 | Jardiance |
| Amgen INC. | $154.76 | 2019-2024 | Tavneos, Aranesp |
| Vifor Pharma, INC. | $149.94 | 2020-2024 | Veltassa |
| Glaxosmithkline, LLC. | $109.39 | 2021-2024 | Benlysta, Jesduvroq |
| Scpharmaceuticals INC. | $102.73 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $93.92 | 2024-2025 | |
| Fresenius USA Marketing, INC. | $90.78 | 2023-2025 | Velphoro, Korsuva, Velphoro |
| Lilly USA, LLC | $81.86 | 2024-2025 | Jardiance |
| Travere Therapeutics, INC. | $63.54 | 2021-2024 | |
| Ani Pharmaceuticals, INC. | $48.42 | 2022 | |
| Calliditas Therapeutics US INC. | $33.08 | 2022-2024 | |
| Vantive US Healthcare LLC | $32.73 | 2025 | Renal - Acute |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $30.57 | 2019-2021 | |
| Kyowa Kirin, INC. | $28.73 | 2024 | Crysvita |
| Akebia Therapeutics INC | $28.66 | 2025 | Vafseo |
| Alexion Pharmaceuticals, INC. | $27.81 | 2019-2024 | Ultomiris |
| Nxstage Medical, INC. | $16.28 | 2024 | |
| Horizon Therapeutics Plc | $15.44 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Bashir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.